Publicacións nas que colabora con Begoña Villar Cheda (25)

2024

  1. Angiotensin type 1 receptor activation promotes neuronal and glial alpha-synuclein aggregation and transmission

    npj Parkinson's Disease, Vol. 10, Núm. 1

2022

  1. Angiotensin Type-1 Receptor Inhibition Reduces NLRP3 Inflammasome Upregulation Induced by Aging and Neurodegeneration in the Substantia Nigra of Male Rodents and Primary Mesencephalic Cultures

    Antioxidants, Vol. 11, Núm. 2

2021

  1. Nadph-oxidase, rho-kinase and autophagy mediate the (Pro)renin-induced pro-inflammatory microglial response and enhancement of dopaminergic neuron death

    Antioxidants, Vol. 10, Núm. 9

  2. The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

    Progress in Neurobiology, Vol. 199

2020

  1. Aging-Related Overactivity of the Angiotensin/AT1 Axis Decreases Sirtuin 3 Levels in the Substantia Nigra, Which Induces Vulnerability to Oxidative Stress and Neurodegeneration

    The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 75, Núm. 3, pp. 416-424

2018

  1. Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans

    Molecular Neurobiology, Vol. 55, Núm. 7, pp. 5847-5867

2017

  1. Insulin-like growth factor-1 and neuroinflammation

    Frontiers in Aging Neuroscience

  2. The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system

    Cell death & disease, Vol. 8, Núm. 9, pp. e3044

2016

  1. Aging-related Increase in Rho Kinase Activity in the Nigral Region is Counteracted by Physical Exercise

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 71, Núm. 10, pp. 1254-1257

  2. Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration

    Cell Death and Disease, Vol. 7, Núm. 10

2015

  1. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Aging-related dysregulation of dopamine and angiotensin receptor interaction

    Neurobiology of Aging, Vol. 35, Núm. 7, pp. 1726-1738

  2. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA

    Neuropharmacology, Vol. 76, Núm. PART A, pp. 156-168

  3. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death

    Neuropharmacology, Vol. 85, pp. 1-8

2013

  1. Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

    Movement Disorders, Vol. 28, Núm. 10, pp. 1337-1342

  2. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: An intracellular renin-angiotensin system in the nigra

    Brain Structure and Function, Vol. 218, Núm. 2, pp. 373-388

2012

  1. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

    Neurobiology of Aging, Vol. 33, Núm. 1, pp. 204.e1-204.e11

  2. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

    American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244

  3. Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: Role of the brain angiotensin system

    Brain, Vol. 135, Núm. 1, pp. 124-138

  4. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

    Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279